Parallel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Parallel Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$730	Hold	100	–	–	﹤0.01%	3834
2026 Q2	$1.08K	Hold	100	–	–	﹤0.01%	3672
2026 Q1	$1.11K	Hold	100	–	–	﹤0.01%	3521
2025 Q4	$1.66K	Sell	100 -86	-46%	-$1.23K	﹤0.01%	3180
2025 Q3	$2.19K	Hold	186	–	–	﹤0.01%	3022
2025 Q2	$1.78K	Sell	186 -143	-43%	-$791	﹤0.01%	3066
2025 Q1	$2.06K	Buy	+329	New	+$2K	﹤0.01%	2969
2023 Q1	–	Sell	-29	Closed	-$325	–	3482
2022 Q4	$325	Hold	29	–	–	﹤0.01%	3115
2022 Q3	$0	Buy	+29	New	+$276	﹤0.01%	3408
2022 Q2	–	Sell	-80	Closed	-$1K	–	3265
2022 Q1	$1K	Buy	80 +8	+11%	+$129	﹤0.01%	2808
2021 Q4	$1K	Buy	+72	New	+$1.69K	﹤0.01%	2932

Other funds holding PHAT

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Penn Mutual Asset Management Conshohocken, Pennsylvania $23.1M AUM 4.22% 1-Year Est. Return

Parallel Advisors's PHAT Position: Q3 2026 in Review

Parallel Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q3 2026 at 100 shares worth $730. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Parallel Advisors first reported a position in PHAT in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.19K in Q3 2025. 33 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

Parallel Advisors held 100 shares of Phathom Pharmaceuticals worth $730 as of Q3 2026.
Parallel Advisors left its Phathom Pharmaceuticals share count unchanged in Q3 2026.
Phathom Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3834 holding.
Parallel Advisors first reported a position in Phathom Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Parallel Advisors's Phathom Pharmaceuticals position peaked at $2.19K in Q3 2025.
33 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.